(Q35070445)

6 August 2017

1 reference

title

Antibody-based therapeutics in oncology (English)

1 reference

6 August 2017

Jeffreys Ross

1

1 reference

6 August 2017

Karen Gray

2

1 reference

6 August 2017

David Schenkein

3

1 reference

6 August 2017

Barry Greene

4

1 reference

6 August 2017

Gary S Gray

5

1 reference

6 August 2017

Jeanine Shulok

6

1 reference

6 August 2017

Peter J Worland

7

1 reference

6 August 2017

Abbie Celniker

8

1 reference

6 August 2017

Mark Rolfe

9

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Expert Review of Anticancer Therapy

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

107-121

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

Monoclonal antibodies in the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

From molecular changes to customised therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

Clinical issues in antibody design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

Monoclonal antibody therapy for lymphoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

PSMA specific antibodies and their diagnostic and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.3.1.107

21 January 2018

Identifiers

DOI

10.1586/14737140.3.1.107

1 reference

6 August 2017

1 reference